- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:10 | Silo Pharma erhält US-Patentzusage für PTSD-Therapeutikum | 1 | Investing.com Deutsch | ||
| 15:06 | Silo Pharma receives U.S. patent allowance for PTSD treatment | 2 | Investing.com | ||
| 14:54 | Silo Pharma, Inc.: Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio | 144 | GlobeNewswire (Europe) | Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo"... ► Artikel lesen | |
| 09.09. | Silo Pharma, Inc.: Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum | 1 | GlobeNewswire (USA) | ||
| 18.08. | Silo Pharma erhält kanadische Patentzulassung für PTSD-Wirkstoff SPC-15 | 2 | Investing.com Deutsch | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| 18.08. | Silo Pharma receives Canadian patent allowance for SPC-15 drug | 2 | Investing.com | ||
| 18.08. | Silo Pharma, Inc.: Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment | 442 | GlobeNewswire (Europe) | Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026... ► Artikel lesen | |
| 17.08. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Silo Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 10.08. | Silo Pharma, Inc.: Silo Pharma Granted European Patent Covering Novel PTSD Therapy | 491 | GlobeNewswire (Europe) | Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop SARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 06.08. | Silo Pharma, Inc.: Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform | 3 | GlobeNewswire (USA) | ||
| 21.07. | Silo Pharma, Inc.: Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program | 2 | GlobeNewswire (USA) | ||
| 14.07. | Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership | 10 | Benzinga.com | ||
| 14.07. | Silo Pharma-Tochter QwikAgents tritt AMD KI-Entwicklerprogramm bei | 18 | Investing.com Deutsch | ||
| 14.07. | Silo Pharma, Inc.: Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform | 9 | GlobeNewswire (USA) | ||
| 10.07. | Silo Pharma Sinks on Stock Sale | - | Baystreet.ca | ||
| 10.07. | Aktien im Fokus: CCC Intelligent Solutions und Circle legen vorbörslich zu, Silo Pharma und Fermi America unter Druck | 3 | Investing.com Deutsch | ||
| 10.07. | Silo Pharma raises $4M in private placement; shares down | 4 | Seeking Alpha | ||
| 10.07. | Silo Pharma raises $4 million in private placement | 3 | Investing.com | ||
| 10.07. | Silo Pharma sichert sich 4 Millionen US-Dollar durch Privatplatzierung | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,05 | -1,16 % | Biontech-Großaktionär rechnet mit baldiger Vorstands-Neubesetzung | Mainz - Einer der Großaktionäre und Mitgründer von Biontech, Thomas Strüngmann, rechnet mit einer baldigen Neubesetzung im Vorstand des Mainzer Biotechunternehmens."Die Berufung eines neuen Medizinvorstands... ► Artikel lesen | |
| VALNEVA | 2,871 | +0,91 % | Valneva-Aktie im Check am 18.09. (08:01 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 333,50 | +0,80 % | Amgen-Aktie: Kann man jetzt schon ein Schnäppchen machen? | Es ist eine bislang miserable Handelswoche für die Amgen-Aktie. Seit Wochenbeginn ging es mit dem Kurs des US-Biopharmariesen um über -13% bergab. Was zieht Amgen dieser Tage in den Kurskeller und können... ► Artikel lesen | |
| NOVAVAX | 8,590 | -1,38 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 191,10 | +0,21 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| ILLUMINA | 210,00 | -1,69 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,825 | -0,27 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| PALATIN TECHNOLOGIES | 10,370 | -0,58 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,912 | +2,13 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,550 | -0,20 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INTELLIA THERAPEUTICS | 10,800 | +1,12 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| TEMPUS AI | 67,81 | -3,07 % | Tempus AI plans 100,000 whole genome sequencing dataset | ||
| EDITAS MEDICINE | 2,370 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,110 | -0,89 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,456 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen |
Das Unternehmen SILO PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,91 % bei einem Aktienkurs von 1,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILO PHARMA INC finden Sie auf Wallstreet Online.